Resources

First-phase insulin secretion: In response to i.v. glucose, insulin is secreted in a biphasic pattern with an early burst of insulin release within the first 10 min followed by a progressively increasing phase of insulin secretion that persists as long as the hyperglycemic stimulus is present. This biphasic insulin response is not observed after oral glucose, because of the more gradual rise in plasma glucose concentration. Loss of first-phase insulin secretion is a characteristic and early abnormality in patients destined to develop T2DM.

In this Exclusive Interview transcript, Grenye O'Malley talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about her prenatal diabetes research, the changes that happen for women with type 1 who are pregnant and using insulin pump therapy, and a large multiple trial for the artificial pancreas.

In this Exclusive Interview, Grenye O'Malley talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about the changes that happen for women with type 1 who are pregnant and using insulin pump therapy.

In part 1 of this Exclusive Interview, Grenye O'Malley talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about the challenges faced by women with diabetes who are pregnant and using an insulin pump.

In part 2 of this Exclusive Interview, Grenye O'Malley talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about the findings of the prenatal study of women with diabetes, both before pregnancy and during. Also, the impact of the CGM on pregnancy.

In part 3, the conclusion of this Exclusive Interview, Grenye O'Malley talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about the unique aspects of a new trial that studies the artificial pancreas and the benefits for people on multiple daily injections who may not want to use a pump.

Key ADA poster summaries include liraglutide in type 1 diabetes, oral semaglutide, bottled water's association with type 2 diabetes, & SGLT-2 combo LIK066.

ADA 2018 abstracts of interest include Entresto for the Treatment of Diabetic Peripheral Neuropathy; Oral Contraceptive Associated with Postmenopausal Diabetes; Glucokinase as Adjunct Therapy in People with Type 1 Diabetes, and more.

Overview from a presentation at the 2018 American Diabetes Associations 78th Scientific Sessions.

The “artificial pancreas” provides glucose control for non-critically ill patients